Exelixis Inc Payments of Stock Issuance Costs
Exelixis Inc (EXEL) had Payments of Stock Issuance Costs of $400.00 thousand as of 2015-07-29, per its 10-Q filed 2015-11-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2015-11-10
- 2015-07-29: Payments of Stock Issuance Costs $400.00K.
- 2012-08-14: Payments of Stock Issuance Costs 0 month $500.00K.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 0 month |
|---|---|---|
| 2015-07-29 | $400.00K 10-Q · filed 2015-11-10 | |
| 2012-08-14 | $500.00K 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |